Jasper Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 4, 2026, 8:11 a.m. ETView on SEC.gov Our explainer
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedJasper Therapeutics announces 1-for-30 reverse stock split effective November 6, 2026, cutting outstanding shares from about 33.3 million to about 1.1 million
8-KOct. 15, 2026, 8 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KOct. 7, 2026, 8:05 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedJasper Therapeutics Launches $0.324-Per-Warrant Cash Tender Offer Costing About $4.0 Million
8-KOct. 5, 2026, 8 a.m. ETView on SEC.gov
Submission of matters to a vote of security holders
8-KSept. 28, 2026, 4:44 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 26, 2026, 4:15 p.m. ETView on SEC.gov
Entry into a material definitive agreement
8-KAug. 14, 2026, 4:07 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 3, 2026, 4:47 p.m. ETView on SEC.gov
Submission of matters to a vote of security holders
8-KJuly 31, 2026, 6:06 a.m. ETView on SEC.gov
Other events